BE

Selvita to acquire Fidelta from Galapagos

Monday, November 23, 2020 - 9:15pm

Mechelen, Belgium and Krakow, Poland 23 November 2020, 22.15 CET Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] announced today that they have signed an agreement under which Selvita will acquire 100% of the outstanding shares in Fidelta d.o.o.

Key Points: 
  • Mechelen, Belgium and Krakow, Poland 23 November 2020, 22.15 CET Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] announced today that they have signed an agreement under which Selvita will acquire 100% of the outstanding shares in Fidelta d.o.o.
  • Fidelta is a contract research organization within the Galapagos Group of companies, with core scientific competences in inflammation, fibrosis, and anti-infectives.
  • Fidelta is located in state-of-the art R&D facilities in Zagreb, Croatia which offer almost 6,000 m2 of research space.
  • Upon completion of the acquisition, Fidelta will be fully consolidated under the Selvita Group, and will continue to operate under the Fidelta name.

'BTS POP-UP : MAP OF THE SOUL' Opened Its Doors in Asia

Monday, November 23, 2020 - 5:13am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201122005100/en/
    BTS new pop-up store BTS POP-UP : MAP OF THE SOUL ONLINE STORE ASIA has launched across seven countries including Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam from 14 November 2020.
  • The BTS POP-UP : MAP OF THE SOUL ONLINE STORE ASIA has opened on the exclusive website called morningKall (2020btspopupasia.morningkall.com) and it is running to 14 February 2021.
  • The BTS POP-UP : MAP OF THE SOUL ONLINE STORE ASIA has opened on November 14th on the exclusive website called morningKall ( 2020btspopupasia.morningkall.com ) and it is running successfully.
  • To find out more about BTS POP-UP ONLINE STORE ASIA and its upcoming releases, visit https://2020btspopupasia.morningkall.com/ or follow @morningKall on Instagram, Facebook and Twitter.

VulcanVerse recruits Gorillaz and U.N.K.L.E Members to Join Blockchain Game Craze

Saturday, November 21, 2020 - 12:00pm

"Both Jeff and Pablo have been making a variety of backing tracks for each 'quadrant' of VulcanVerse.

Key Points: 
  • "Both Jeff and Pablo have been making a variety of backing tracks for each 'quadrant' of VulcanVerse.
  • We wanted a set of modern yet experimental tracks for users to enjoy based on each area of the world they were in.
  • Jeff's experimental and ambient guitar style fit the desert lands and underworld, while Pablo's new band ToyDrum were perfect for the mountains and cities.
  • VulcanVerse sold out their land to users in September and the game goes live end of December 2020.

Nyxoah to Participate in Annual Piper Sandler Healthcare Conference

Friday, November 20, 2020 - 6:24am

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions.

Key Points: 
  • Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions.
  • Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in March 2019.
  • Limited by U.S. federal law to investigational use in the United States.
  • 1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep.

Sequana Medical Announces Positive Interim Data From North American Pivotal alfapump® Study (POSEIDON)

Thursday, November 19, 2020 - 7:00am

Patients from the Roll-In cohort will upon implementation of the inclusion/exclusion criteria, immediately be implanted with the alfapump.

Key Points: 
  • Patients from the Roll-In cohort will upon implementation of the inclusion/exclusion criteria, immediately be implanted with the alfapump.
  • The primary safety endpoint is the rate of alfapump related re-interventions adjudicated by the Clinical Events Committee.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)

Thursday, November 19, 2020 - 7:00am

Patients from the Roll-In cohort will upon implementation of the inclusion/exclusion criteria, immediately be implanted with the alfapump.

Key Points: 
  • Patients from the Roll-In cohort will upon implementation of the inclusion/exclusion criteria, immediately be implanted with the alfapump.
  • The primary safety endpoint is the rate of alfapump related re-interventions adjudicated by the Clinical Events Committee.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

SCHRÉDER APPOINTS NEW GENERAL MANAGER - NORTH AMERICA, STEVE MILLS

Wednesday, November 18, 2020 - 8:30pm

Brussels, Belgium, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Schrder Group, the world leading independent outdoor lighting provider, is proud to announce that it has appointed Steve Mills as General Manager - North America, in charge of the United States of America and Canada.

Key Points: 
  • Brussels, Belgium, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Schrder Group, the world leading independent outdoor lighting provider, is proud to announce that it has appointed Steve Mills as General Manager - North America, in charge of the United States of America and Canada.
  • For the past year, Steve has been working with Schrder as a consultant and has been appointed to General Manager North America, working full-time for Schrder, since September 2020.
  • Steve is also a Board Member of EMX Industries, Inc. and Buffalo United Group, specializing in access control & specialty industrial sensors and construction markets, respectively.
  • Steve has been a very professional adviser to Schrder, with extensive knowledge of the North American market.

BTS Recognized as a Great Place to Work-Certified™ Company in 2020

Tuesday, November 17, 2020 - 3:02pm

BTS Group AB (publ), a world-leading strategy implementation firm, earned the honor Great Place to Work-Certified.

Key Points: 
  • BTS Group AB (publ), a world-leading strategy implementation firm, earned the honor Great Place to Work-Certified.
  • Great Place to Work is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue and increased innovation.
  • We are thrilled to be Great Place to Work-Certified, says Melissa Friedman, Head of People Experience at BTS.
  • We congratulate BTS on their Certification, said Sarah Lewis-Kulin, Vice President of Best Workplace List Research at Great Place to Work.

First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)

Tuesday, November 17, 2020 - 6:00am

The implantation took place at Hollywood Private Hospital in Perth, Australia and was performed by Dr. Richard Lewis, MBBS, FRACS, Head & Neck Surgeon.

Key Points: 
  • The implantation took place at Hollywood Private Hospital in Perth, Australia and was performed by Dr. Richard Lewis, MBBS, FRACS, Head & Neck Surgeon.
  • The DREAM (Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is a pivotal, Investigational Device Exemption (IDE) trial designed to support the marketing authorization of the Genio system in the United States.
  • Olivier Taelman, Chief Executive Officer of Nyxoah, added: The United States are the largest market in the world for the treatment of patients suffering from Obstructive Sleep Apnea.
  • The DREAM study is designed to support the U.S.introductionof the Genio system.

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

Thursday, November 12, 2020 - 6:00am

The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed 3 billion annually within the next 10-20 years.

Key Points: 
  • The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed 3 billion annually within the next 10-20 years.
  • Both indications leverage Sequana Medical's alfapump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.
  • Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure.
  • You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.